Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy

Rajshekhar Chakraborty, Saurabh Zanwar, Ute Hegenbart, Divaya Bhutani, Morie A. Gertz, Angela Dispenzieri, Shaji Kumar, Anita D’Souza, Anannya Patwari, Andrew Cowan, GuiZhen Chen, Paolo Milani, Giovanni Palladini, Vaishali Sanchorawala, Geethika Bodanapu, Stefan O. Schönland, Suzanne Lentzsch, Eli Muchtar

Blood (2024) 144 (25): 2613–2624.

https://doi.org/10.1182/blood.2024025899

Published: 2024

Includes: Supplemental data

Journal Articles

Development of a Risk Prediction Model for 6-Month Early Mortality in Patients with Systemic Light Chain Amyloidosis Treated with Daratumumab-Based Frontline Therapy

Blood (2024) 144 (Supplement 1): 287.

https://doi.org/10.1182/blood-2024-202589

Published: 2024

Journal Articles

Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study

Blood (2024) 144 (Supplement 1): 4733.

https://doi.org/10.1182/blood-2024-200071

Published: 2024

Journal Articles

Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria

Christoph R. Kimmich, Tobias Terzer, Axel Benner, Tobias Dittrich, Kaya Veelken, Alexander Carpinteiro, Timon Hansen, Hartmut Goldschmidt, Anja Seckinger, Dirk Hose, Anna Jauch, Stefan Wörner, Jörg Beimler, Carsten Müller-Tidow, Ute Hegenbart, Stefan O. Schönland

Blood (2020) 135 (18): 1517–1530.

https://doi.org/10.1182/blood.2019003633

Published: 2020

Includes: Supplemental data

Journal Articles

High-Throughput Immunofluorescence and Electron Tomography to Characterize Centrosomal Aberrations in Plasma Cell Neoplasia

Tobias Dittrich, MD, Martin Schorb, Isabella Haberbosch, MD, Elena Bausch, PhD, Mandy Börmel, Marco Cosenza, PhD, Hartmut Goldschmidt, MD, Carsten Müller-Tidow, MD, Marc S Raab, MD PhD, Ute Hegenbart, MD, Stefan O. Schönland, MD, Yannick Schwab, PhD, Alwin Krämer, MD

Blood (2019) 134 (Supplement_1): 3077.

https://doi.org/10.1182/blood-2019-130713

Published: 2019

Journal Articles

Comparison of Different Upfront Transplant Strategies in Multiple Myeloma - a Large Registry Study from Chronic Malignancies Working Party of EBMT

Blood (2019) 134 (Supplement_1): 324.

https://doi.org/10.1182/blood-2019-128795

Published: 2019

Journal Articles

Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL)

Angela Dispenzieri, MD, Eftathios Kastritis, Ashutosh D Wechalekar, MB BS, MD FRCP, FRCPath, DM, Stefan O. Schönland, MD, Kihyun Kim, MD, Vaishali Sanchorawala, MD, Heather J Landau, MD, Fiona Kwok, FRACP,FRCPA,MBBS, Kenshi Suzuki, MD PhD, Raymond L Comenzo, MD, Deborah Berg, RN, MSN, Guohui Liu, PhD, Douglas V. Faller, MD PhD, Giampaolo Merlini, MD

Blood (2019) 134 (Supplement_1): 139.

https://doi.org/10.1182/blood-2019-124409

Published: 2019

Journal Articles

Safety and Efficacy of Autologous Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients - the Diadem Study from the Chronic Malignancies Working Party of the EBMT

Blood (2019) 134 (Supplement_1): 4574.

https://doi.org/10.1182/blood-2019-127238

Published: 2019

Journal Articles

Trends in Autologous Transplantation for Myeloma in EBMT Centres between 1993 and 2017

Blood (2019) 134 (Supplement_1): 4575.

https://doi.org/10.1182/blood-2019-127166

Published: 2019

Journal Articles

OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis

Giovanni Palladini, MD PhD, Stefan O. Schönland, MD, Suzanne Lentzsch, MD PhD, M. Teresa Cibeira, MD PhD, Roman Hajek, Prof, MD PhD, Arnaud Jaccard, MD PhD, Krzysztof Jamroziak, MD PhD, Eftathios Kastritis, Vaishali Sanchorawala, MD, Fredrik H. Schjesvold, MD PhD, Ashutosh D Wechalekar, MBBS, MD FRCP, FRCPath, DM, Sara Thuresson, MSc, Johan Harmenberg, MD PhD, Catriona Byrne, RN, Giampaolo Merlini, MD

Blood (2019) 134 (Supplement_1): 3163.

https://doi.org/10.1182/blood-2019-124244

Published: 2019

Journal Articles

Maintaining the Cellular Anti-Viral and Anti-Leukemic Activities in GvHD Patients Undergoing Extracorporeal Photophoresis Therapy

Ruben A. Gößmann, Lei Wang, MD, Ming Ni, Mingya Yang, MD, Thomas Luft, Ute Hegenbart, MD, Stefan O. Schönland, MD, Patrick Wuchter, MD, Volker Eckstein, William Hermann Krüger, MD PhD, Ronit Yerushalmi, MD, Katia Beider, Arnon Nagler, MD MSc, Carsten Müller-Tidow, MD, Peter Dreger, Michael Schmitt, MD, Anita Schmitt, MD

Blood (2019) 134 (Supplement_1): 3287.

https://doi.org/10.1182/blood-2019-125049

Published: 2019

Journal Articles

A Semi-Automated Knime-Based Workflow for High Throughput Quantification and Analysis of Centrosome Aberrations

Tobias Dittrich, MD, Elena Bausch, PhD, Johannes Bausch, PhD, Hartmut Goldschmidt, MD, Ute Hegenbart, MD, Stefan O. Schönland, MD, Marc S Raab, MD PhD, Alwin Krämer, MD

Blood (2019) 134 (Supplement_1): 3379.

https://doi.org/10.1182/blood-2019-129863

Published: 2019

Journal Articles

Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients

Morie A Gertz, MD, Adam D. Cohen, MD, Raymond L Comenzo, MD, Charles Du Mond, Eftathios Kastritis, Heather J Landau, MD, Edward N. Libby, III, MD, Michaela Liedtke, MD, Giampaolo Merlini, MD, Vaishali Sanchorawala, MD, Stefan O. Schönland, MD, Ashutosh D Wechalekar, MBBS, MD FRCP, FRCPath, DM, Jeffrey A. Zonder, Gene Kinney, PhD

Blood (2019) 134 (Supplement_1): 3166.

https://doi.org/10.1182/blood-2019-124482

Published: 2019

Journal Articles

First report of ibrutinib in IgM-related amyloidosis: few responses, poor tolerability, and short survival

Tomas Pika, Ute Hegenbart, Pavla Flodrova, Bettina Maier, Christoph Kimmich, Stefan O. Schönland

Blood (2018) 131 (3): 368–371.

https://doi.org/10.1182/blood-2017-09-806463

Published: 2018

Journal Articles

AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis

Tobias Dittrich, Tilmann Bochtler, Christoph Kimmich, Natalia Becker, Anna Jauch, Hartmut Goldschmidt, Anthony D. Ho, Ute Hegenbart, Stefan O. Schönland

Blood (2017) 130 (5): 632–642.

https://doi.org/10.1182/blood-2017-02-767475

Published: 2017

Includes: Supplemental data

Journal Articles

A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis

Vaishali Sanchorawala, Giovanni Palladini, Vishal Kukreti, Jeffrey A. Zonder, Adam D. Cohen, David C. Seldin, Angela Dispenzieri, Arnaud Jaccard, Stefan O. Schönland, Deborah Berg, Huyuan Yang, Neeraj Gupta, Ai-Min Hui, Raymond L. Comenzo, Giampaolo Merlini

Blood (2017) 130 (5): 597–605.

https://doi.org/10.1182/blood-2017-03-771220

Published: 2017

Journal Articles

Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study

Tilmann Bochtler, Ute Hegenbart, Christina Kunz, Axel Benner, Christoph Kimmich, Anja Seckinger, Dirk Hose, Hartmut Goldschmidt, Martin Granzow, Peter Dreger, Anthony D. Ho, Anna Jauch, Stefan O. Schönland

Blood (2016) 128 (4): 594–602.

https://doi.org/10.1182/blood-2015-10-676361

Published: 2016

Includes: Supplemental data

Journal Articles

Low Pre-Transplant Levels of 25-Hydroxyvitamin D3 Predict Relapse and Survival in Male but Not in Female Patients Undergoing Allogeneic Stem Cell Transplantation

Aleksandar Radujkovic, MD, Axel Benner, Sascha Dietrich, MD, Ute Hegenbart, MD, Stefan O Schönland, Anthony D. Ho, MD FRCPC, Peter Dreger, MD, Thomas Luft, MD PhD

Blood (2014) 124 (21): 1181.

https://doi.org/10.1182/blood.V124.21.1181.1181

Published: 2014

Journal Articles

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

Blood (2014) 124 (21): 35.

https://doi.org/10.1182/blood.V124.21.35.35

Published: 2014

Journal Articles

Lenalidomide/Melphalan / Dexamethasone Chemotherapy In 50 Patients With Newly Diagnosed Amyloid Light Chain Amyloidosis: First Results Of a Prospective Single Center Phase 2 Study (Leomex)

Stefan O Schonland, MD, Tilmann Bochtler, MD, Axel Benner, Marianne Gawlik, Christoph Kimmich, Arnt V Kristen, Jörg Beimler, Anthony D. Ho, MD, Ute Hegenbart, MD

Blood (2013) 122 (21): 1993.

https://doi.org/10.1182/blood.V122.21.1993.1993

Published: 2013

NARROW

Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy

Development of a Risk Prediction Model for 6-Month Early Mortality in Patients with Systemic Light Chain Amyloidosis Treated with Daratumumab-Based Frontline Therapy

Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study

Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria

High-Throughput Immunofluorescence and Electron Tomography to Characterize Centrosomal Aberrations in Plasma Cell Neoplasia

Comparison of Different Upfront Transplant Strategies in Multiple Myeloma - a Large Registry Study from Chronic Malignancies Working Party of EBMT

Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL)

Safety and Efficacy of Autologous Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients - the Diadem Study from the Chronic Malignancies Working Party of the EBMT

Trends in Autologous Transplantation for Myeloma in EBMT Centres between 1993 and 2017

OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis

Maintaining the Cellular Anti-Viral and Anti-Leukemic Activities in GvHD Patients Undergoing Extracorporeal Photophoresis Therapy

A Semi-Automated Knime-Based Workflow for High Throughput Quantification and Analysis of Centrosome Aberrations

Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients

First report of ibrutinib in IgM-related amyloidosis: few responses, poor tolerability, and short survival

AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis

A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis

Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study

Low Pre-Transplant Levels of 25-Hydroxyvitamin D3 Predict Relapse and Survival in Male but Not in Female Patients Undergoing Allogeneic Stem Cell Transplantation

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

Lenalidomide/Melphalan / Dexamethasone Chemotherapy In 50 Patients With Newly Diagnosed Amyloid Light Chain Amyloidosis: First Results Of a Prospective Single Center Phase 2 Study (Leomex)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only